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Abstract
Objective
Studies have suggested a beneficial effect of angiotensin-converting enzyme (ACE) inhibi-
tion. To explore whether the ACE inhibitor ramipril has a direct effect on the microvascula-
ture beyond the blood pressure (BP) lowering effect, we investigated whether ramipril
improved coronary microvascular function in normotensive women with coronary microvas-
cular dysfunction (CMD).
Methods
We included 63 normotensive women with angina, no epicardial stenosis>50% and CMD
defined as a coronary flow velocity reserve (CFVR)<2.2 assessed by adenosine stress-
echocardiography in a randomized double-blinded, superiority trial with 1:1 allocation to pla-
cebo or ramipril (maximum dose 10 mg depending on blood pressure) for 24±6 weeks. Pri-
mary outcome was CFVR. Secondary outcomes were left ventricular systolic and diastolic
function and symptoms evaluated by Seattle Angina Questionnaire (clinicaltrials.gov,
NCT02525081).
Results
Follow-up was available on 55 patients. BP remained unchanged during treatment in both
groups. CFVR improved in both the ramipril (p = 0.004) and placebo group (p = 0.026) with
no difference between groups (p = 0.63). Symptoms improved in both groups with no signifi-
cant between-group differences. No changes were detected in parameters of systolic and
diastolic function. No serious adverse reactions were reported.
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Conclusions
In normotensive women with angina and CMD, treatment with ramipril had no significant
effect on CFVR or symptoms compared with placebo. The effect of ACE inhibition previ-
ously reported may be mediated by blood pressure reduction.
Introduction
Angina pectoris in the absence of significant obstructive coronary artery disease (CAD) can be
caused by coronary microvascular dysfunction (CMD). CMD causes insufficient coronary
blood flow in situations with increased cardiac oxygen demand leading to transient ischemia
and pain [1]. Up to 40% of patients with angina and no obstructive CAD have CMD [2–4],
which is a predictor of poor cardiovascular prognosis [3]. However, evidence-based treatment
strategies are lacking [5].
Vascular remodelling is suggested as a main pathogenic mechanism of CMD in the absence
of obstructive CAD [1]. By a reduction in blood pressure, antihypertensive treatment should
theoretically increase the blood flow reserve through a reduction in resting coronary flow [6].
However, evidence suggests that treatment with angiotensin-converting enzyme (ACE) inhibi-
tor has an additional beneficial effect. Treatment has been associated with positive vascular
changes beyond the antihypertensive effect and has been suggested to improve both non-endo-
thelial and endothelial dependent CMD [7–11]. Concurrently, treatment with ACE-inhibition
in patients with refractory microvascular angina has received a IIb recommendation in current
guidelines [12]. However, results obtained from interventional studies on the non-endothelial
aspect of CMD have been inconsistent [13–26] and whether the effect observed in some stud-
ies on coronary microvascular function could be indirectly mediated via treatment of hyper-
tension is unclear.
In salt replete normotensive individuals without heart failure, effect of ACE inhibition on
blood pressure is absent or modest [10,27–38]. Therefore, to explore whether the ACE-inhibi-
tor ramipril had a beneficial effect on the coronary microvasculature beyond the blood pres-
sure lowering effect, we designed a 6 months long double blind placebo-controlled study
including only normotensive women. Furthermore, to study whether treatment with ACE
inhibitor is indicated in patients with angina and normal blood pressure.
Methods
Study population
Normotensive women with angina pectoris, no significant obstructive CAD (<50% coronary
artery stenosis) and a history of a coronary flow velocity reserve (CFVR)<2.2 assessed by
transthoracic Doppler echocardiography (TTDE) with dipyridamole infusion in the iPOWER
(ImProve diagnOsis and treatment of Women with angina pEctoris and micRovessel disease)
cohort study were systematically invited [4,39,40]. Normal blood pressure was defined as a
history of systolic blood pressure150 mmHg and no current treatment for hypertension.
Exclusion factors in the iPOWER cohort are described in detail in previous publications
[4,39]. In short, participants had no previous history of myocardial infarction, valvular- or
congenital heart disease, no severe pulmonary disease and a left ventricular ejection fraction
(LVEF) above 45%. Further exclusion factors in this trial were atrial fibrillation, pacemaker,
ACE inhibitor or angiotensin II-antagonist treatment, no angina symptoms within 6 months
ACE-inhibitor and Microvascular Function
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Abbreviations: ACE, Angiotensin-converting
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volume in 1 second; GLS, Global longitudinal
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Doppler echocardiography; ΔGLS, Absolute
increase of global longitudinal strain; ΔLVEF,
Absolute increase of left ventricular ejection
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and an estimated glomerular filtration rate (eGFR)<50 mL/min/1.73m2. At study baseline
examination (initial screening), participants with a baseline CFVR>2.5 indicating no CMD
assessed by TTDE with adenosine stress or baseline systolic blood pressure >150 mmHg were
excluded.
Study design
This study is a randomized placebo-controlled two-arm parallel, superiority trial with 1:1 allo-
cation to treatment with the oral ACE inhibitor, ramipril, and an oral matching placebo, as
add-on to usual treatment. After baseline measurements participants were randomized in
blocks of 10 participants by the pharmacy (Glostrup Apotek, Copenhagen, Denmark). The
allocation sequence was concealed in sealed opaque envelopes until the end of the study. Par-
ticipants, health care providers and data collectors were blinded.
Project medication was up titrated at hospital visits to the highest dose possible according
to blood pressure level and side effects following the algorithm depicted in Fig 1. In guidelines
or clinical trials the maximum dose of ramipril for treatment of hypertension, heart failure and
secondary prevention after myocardial infarction is 10 mg [41–43]. A trial overview is depicted
in Fig 2. Kidney function was controlled at each visit by analysing blood samples for creatinine
level and estimation of glomerular filtration rate (eGFR). A research assistant, who was not
performing the primary endpoint measurements, was in charge of hospital visits and control
of adverse events. The pre-specified primary endpoint was CFVR, which was performed by an
operator, who had no other contact with the participants. The pre-specified secondary end-
points were the burden of symptoms and parameters of left ventricular systolic and diastolic
function measured by TTDE. Examinations were performed at baseline and after 24±6 weeks.
The project medication was discontinued 24 hours before the final measurements. After trial
commencement no study changes were made.
Examinations
Assessment included clinical and demographic data. Trained health professionals interviewed
participants regarding cardiovascular risk factors including age, body mass index, diabetes,
hypertension, and hyperlipidaemia, smoking and family history of cardiovascular disease.
Blood pressure and heart rate measures were obtained at rest as the mean of 3 measurements
obtained with 3-minute intervals.
Seattle Angina Questionnaire was used to evaluate the burden of symptoms, which were 5
dimensions of functional status: physical limitation, angina stability, angina frequency, treat-
ment satisfaction and disease perception. Participants could score between 0 and 100, and a
high score equalled a higher functional status [44].
Echocardiographic examination
Participants underwent a standard resting transthoracic echocardiography (TTE) using GE
Healthcare Vivid E9 cardiovascular ultrasound system (GE Healthcare, Horten, Norway) with
a 1.3–4.0 MHz transducer (GE Vivid 5S probe). Images were stored for off-line analysis (GE
EchoPAC v.112, Norway). The same experienced echocardiographer, who was blinded to all
participant data, performed all image acquisition and analyses at Bispebjerg University Hospi-
tal (Copenhagen, Denmark). Before examinations, participants were instructed to be abstinent
from caffeine and food containing a significant amount of methylexanthine (coffee, tea, choco-
late, cola and banana) for 24 hours. Medication containing dipyridamole was paused for 48
hours, anti-ischemic agents (long-lasting nitroglycerine, beta-blockers, calcium antagonist,
ivabradine etc.), anti-hypertensive medication including project medication and diuretics for
ACE-inhibitor and Microvascular Function
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24 hours and short-lasting nitroglycerine one hour before the examination. Before the exami-
nation, abstinence of the abovementioned food and medication was confirmed.
Examination at rest: LVEF, GLS and parameters of diastolic function. We acquired
2-dimensional images of the left ventricle in apical long axis, 2- and 4-chamber views at frame
rates between 60–90 frames/s adjusted as close to the patient’s heart rate as possible. Global
longitudinal strain (GLS) was measured using software for speckle tracking analysis (Q-analy-
sis, GE EchoPAC v.112, Norway). Aortic valve closure was defined in tissue Doppler M-mode.
The left ventricular endocardial border was traced in all three views, and the automatically cre-
ated region of interest was manually adjusted until tracking was considered optimal. Segments
were discarded if tracking was persistently poor. Subsequently, deformation parameters were
automatically obtained for all accepted left ventricular segments and GLS was calculated as the
Fig 1. Up titration of project medication. Blood pressure (BP) will be controlled after each visit. If possible treatment dose (per day) is increased. If patients have
adverse reactions, project medication dose will be reduced. The least acceptable dose for staying in the study is 2.5 mg per day.
https://doi.org/10.1371/journal.pone.0196962.g001
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average of these [45]. We have previously reported good inter-analyser reproducibility for GLS
[39]. In a sub-analysis testing robustness of results, only 3 discarded segments were permitted.
LVEF was analysed as a semi-automated biplane calculation (Auto-EF tool, GE EchoPAC
v.112, Norway). Measurements of left ventricular internal dimensions, left ventricle mass
index (LVMI), and left atrium volume index (LAVI) by the ‘Volume Method of Discs’ were
performed and calculated according to European and American recommendations [46,47].
Echocardiographic parameters of diastolic function including the early (E) and late (A) mitral
inflow velocities, tissue Doppler early and late diastolic velocities in the lateral mitral annulus
(e’ and a’) and the E/A and e’/a’-ratios were used as surrogates of myocardial relaxation and
left ventricular compliance, the deceleration time as a surrogate of early left ventricular stiff-
ness and, E/e’ as a surrogate estimate of left ventricular filling pressures [47]. All measures
were averaged over 3 heart cycles. In case of fusion of the E and A or e’ and a’ waves, measure-
ments were registered as missing.
Left ventricular filling pressure was categorized as normal or high by a modified algorithm
from the recommendations of the American and European Societies of Echocardiography
concerning patients with preserved left ventricular ejection fraction (LVEF), i.e. normal filling
pressure if E/e’<8 or E/e’ 8–12 and LAVI<34 mL/m2, and high filling pressure if E/e’ 8–12
and LAVI>34 or E/e’>12, respectively [47].
All parameters were reviewed for outliers by histogram plots and pre-specified cut-offs.
Adenosine stress examination: CFVR and left ventricular contractile reserve. TTDE of
the left anterior descending artery during rest and adenosine infusion (0.84 mg/kg) over 6
minutes to obtain coronary flow velocities (CFV) at baseline and at maximal hyperaemia using
a 2.7–8 MHz transducer (GE Vivid 6S probe) was performed as previously described [4,40].
The primary endpoint, CFVR, was calculated as the ratio between peak diastolic CFV during
hyperaemia and during rest. Two experts, blinded to participant data with no participant con-
tact, analysed every CFVR examination independently. The first reading was used, except for
estimates that differed by>0.2, in which case the two investigators reanalysed the CFVR exam-
ination and reached agreement. In our previous validation study with repeated TTDE CFVR
Fig 2. General study outline. CFVR: Coronary flow reserve velocity, LV: Left ventricular, SAQ: Seattle Angina Questionnaire, eGFR: Estimated
glomerular filtration rate, BP: blood pressure.
https://doi.org/10.1371/journal.pone.0196962.g002
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examinations in 10 young, healthy individuals by the same observer, we found an intraclass
correlation coefficient (CI) of 0.97 (0.92; 1.00) and limits of agreement (2xSD [CI]) was 0.44
(0.21; 0.68). The test-retest properties were similar in a patient population of 10 women with
angina and no obstructive CAD where we found an intraclass correlation coefficient (CI) of
0.90 (0.78; 1.02) and limits of agreement (2xSD [CI]) was 0.48 (0.22; 0.74) [48]. In a sample of
10 participants from the iPOWER study, CFVR readings for the 2 observers were highly repro-
ducible [39]. Two-dimensional images of the left ventricle in apical long axis, 2- and 4-cham-
ber views were acquired at hyperaemia. Strain measurements were analysed as described
above. The left ventricular contractile reserve was assessed as an increase of GLS (ΔGLS) from
rest to peak hyperaemia.
Compliance
A research assistant, who was not in charge of the primary endpoint, performed compliance
telephone calls each month. Furthermore, we had the following information regarding
compliance:
• Participants completed a diary each day indicating whether the daily medication was taken.
• Participants returned excess containers with medication at the end of the study and tablets
were counted.
Compliance was defined as the ratio of project medication actually taken and the calculated
amount of medication prescribed.
Statistical analyses
Prior to study commencement, sample size was estimated to be 60 participants completing the
study. This was based on the detection of a 0.3 change in CFVR (which we judged as clinically
relevant), a power of 90%, and a two–sided significance level of 0.05. We assumed that the SD
on mean difference in CFVR would be 0.4 in the ramipril group and 0.3 for the placebo group
based on previous studies [48,49]. The intention was to include 72 patients due to expected
drop out during the study.
Strict intention-to-treat analysis was not possible due to missing outcomes on participants
who dropped out. A linear mixed model with unstructured covariance (PROC MIXED in
SAS) was used to perform analysis of the primary (CFVR) and secondary endpoints, including
baseline measures on participants who dropped out (analyses were adjusted for baseline value
of the outcome studied) [50]. A supplementary analysis investigating the treatment effect on
the primary outcome parameter, CFVR, adjusted for resting systolic blood pressure and rest-
ing heart rate was performed. Furthermore, a subanalysis stratifying on project medication
dosage prescribed was performed. This was not pre-specified in the protocol. We also per-
formed a per protocol analysis including only participants with follow-up completed.
Model control included assumptions of linearity, variance homogeneity, and Gaussian dis-
tribution of residuals.
Continuous variables with a Gaussian distribution were expressed as mean ± standard
deviation (SD), and continuous variables with a non-Gaussian distribution as median ± inter-
quartile range (IQR). A two-sided p-value below 0.05 was considered significant. All analyses
were performed using SAS Enterprise Guide 7.1 (SAS Institute Inc., North Carolina, USA) and
STATA/IC 13.1 (StataCorp LP, College Station, Texas, USA).
ACE-inhibitor and Microvascular Function
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Ethical standard
This study was performed in accordance with the Helsinki Declaration and was approved by
the Danish Regional Committee on Biomedical Research Ethics (H-3-2014-138) and the Dan-
ish Health Authority. Informed consent was obtained from all individual participants included
in the study. The clinical trial is registered as ACIM at clinicaltrials.gov (NCT02525081). Flow
mediated dilation (FMD) was acquired as part of the original protocol, but data was excluded
from the main manuscript due to poor quality of examinations (only 39 patients had a full
FMD dataset). Methodology and results are displayed in the Supplementary material (Tables
A and B in S1 File). The article is presented according to the CONSORT statement. The
authors report no conflicts of interest. All authors have approved the final article.
Results
Population
A total of 201 cohort participants met the inclusion and exclusion criteria. We included 63
women between the 29th of July 2015 and the 30th of November 2015. Last participant follow-
up examination was performed the 28th of April 2016. Eight participants dropped out and final
outcome measures were missing as a loss to follow-up: four in the placebo group due to unre-
lated illness, depression, discomfort and lack of contact and four in the ramipril group due to
discomfort, cough and other unrelated illness (Fig 3). Mean age (SD) for the included partici-
pants and the participants who dropped out was 58.0 (12.3) and 57.7 (9.9), respectively, and
baseline CFVR (SD) was 2.15 (0.32) and 2.11 (0.22), respectively (p>0.05 between included
participants and participants that dropped out). Baseline data are displayed in Table 1.
Uptitration and adherence to project medication
Treatment interval (SD) was 138 (20) and 145 (15) days in the placebo and ramipril group,
respectively. Approximately 40% of participants were prescribed low dose ramipril (2.5mg),
20% were prescribed middle dose (5mg) and 40% high dose ramipril (10mg) (Table 1).
One participant from the placebo group was terminated early after 50 days of treatment
and was not fully up titrated due to discomfort. Further, one participant from the placebo and
one from the ramipril group were not fully up titrated according to blood pressure due to pre-
sumed adverse reactions.
Counting medication left in project medication containers together with patient diary data,
median compliance for patients in the placebo and ramipril group who completed the study
was 97% (IQR 93–98%; min. 85%; max. 100%) and 99% (IQR 98–100%; min. 77%; max
100%), respectively.
Haemodynamics and GFR
Treatment with ramipril did not significantly reduce systolic or diastolic blood pressure com-
pared with placebo (p = 0.91 and p = 0.83, respectively). Heart rate and eGFR did not change
during treatment with ramipril compared with placebo (p = 0.09 and p = 0.60, respectively)
(Table 2).
Primary endpoint: Effect on CFVR
CFVR improved for both participants receiving ramipril (p = 0.004) and placebo (p = 0.026)
with no significant difference in response between the two groups (p = 0.63) (Table 3). Multi-
variable adjustment with resting systolic blood pressure and resting heart rate did not change
results. In a sub-analysis stratifying on final dose of project medication, results obtained for
ACE-inhibitor and Microvascular Function
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participants receiving middle to high dose ramipril (n = 32) were similar to the overall results
with no between-group differences (p-interaction = 0.21).
Results from per protocol analysis were similar to the intention to treat analysis.
Secondary endpoints: Effect on other echocardiographic measures and
burden of symptoms
Outcome measures are displayed in Table 3. There was no effect of treatment with ramipril on
parameters of left ventricular systolic or diastolic function assessed by echocardiography com-
pared with placebo.
Fig 3. Participant flow-chart. 3 CAD: Coronary artery disease. CFVR: Coronary flow velocity reserve, ACE: Angiotensin-converting
enzyme, GFR: Glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0196962.g003
ACE-inhibitor and Microvascular Function
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Table 1. Baseline characteristics.
Placebo (n = 31) Ramipril (n = 32)
Age (years), mean (SD) 57.3 (12.5) 58.6 (11.6)
Body Mass Index, mean (SD) 25.3 (5.4) 27.3 (4.9)
Hypertension, n (%) 0 (0) 0 (0)
Diabetes Mellitus, n (%) 1 (3) 3 (9)
Smoking (current), n (%) 7 (23) 8 (25)
Hypercholesterolaemia, n (%) 12 (39) 19 (59)
Family history of CAD, n (%) 23 (74) 21 (66)
Heart rate (beats/min), mean (SD) 66.2 (10.1) 65.9 (11.3)
Systolic blood pressure (mmHg), mean (SD) 127.4 (11.0) 124.1 (11.0)
Diastolic blood pressure (mmHg), mean (SD) 70.2 (7.7) 67.2 (7.9)
Subclinical atherosclerosis (>0, <50% stenosis at CAG), n (%) 4 (13) 13 (42)
Medication
Acetylsalicylic acid, n (%) 4 (13) 12 (38)
Beta-receptor blockers, n (%) 5 (16) 4 (13)
Statin, n (%) 8 (26) 11 (34)
Calcium antagonist, n (%) 1 (3) 3 (9)
Diuretic, n (%) 3 (10) 5 (16)
Project relevant information
Dosage
2.5 mg, n (%) 11 (41) 12 (43)
5 mg, n (%) 4 (15) 6 (21)
10 mg, n (%) 12 (44) 10 (36)
Treatment interval (days), mean (SD) 138 (20) 145 (15)
Echocardiographic parameters
CFVR, mean (SD) 2.26 (0.26) 2.03 (0.31)
GLS at rest (%), mean (SD) -20.4 (2.5) -21.0 (2.0)
GLS at hyperaemia (%), mean (SD) † -23.1 (2.6) -23.5 (2.3)
ΔGLS (%), mean (SD) † -2.9 (2.3) -2.5 (2.3)
LVEF (%), mean (SD) 52.6 (4.2) 52.0 (4.7)
LVMI (mg/m2), mean (SD) 70.1 (9.8) 72.7 (14.7)
LAI (mL/m2), mean (SD) 26.0 (4.5) 28.0 (8.9)
Deceleration time (ms), mean (SD) † 186.0 (27.9) 198.2 (39.2)
E/A ratio, mean (SD) † 1.02 (0.25) 1.04 (0.32)
e’ (cm/s), mean (SD) † 10.21 (2.85) 10.09 (2.57)
E/e’ ratio, mean (SD) † 6.60 (1.53) 7.03 (1.30)
Burden of symptoms: score by Seattle Angina Questionnaire ‡
Physical limitation, mean (SD) 75.79 (17.46) 74.87 (17.69)
Angina stability, mean (SD) 49.66 (29.58) 51.61 (28.18)
Angina frequency, mean (SD) 65.52 (23.24) 78.44 (20.18)
Treatment satisfaction, mean (SD) 69.79 (23.59) 69.15 (5.71)
Perception/quality of life, mean (SD) 54.17 (19.61) 59.01 (23.52)
CFVR: Coronary flow velocity reserve, GLS: Global longitudinal strain, LVEF: Left ventricular ejection fraction, LVMI: Left ventricular mass index, LAI: Left atrium
volume (method of discs) index,
Only including patients that completed the study.
†A maximum of 6 observations missing (balanced).
‡ A maximum of 8 responses missing (balanced).
https://doi.org/10.1371/journal.pone.0196962.t001
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Table 2. Effect on hemodynamic variables and eGFR.
Placebo (n = 31) Ramipril (n = 32)
Estimated change at 2. visit
(95% CI)
Estimated change at final visit
(95% CI)
Estimated change at 2. visit
(95% CI)
Estimated change at final visit
(95% CI)
p-value 
Systolic BP
(mmHg)
-3.4 (-7.2; 0.3) -0.03 (-3.2; 3.1) -4.1 (-7.7; -0.5) 0.47 (-2.6; 3.5) 0.91
Diastolic BP
(mmHg)
3.7 (0.4; 7.1) 1.5 (-1.0; 4.1) 2.3 (-0.9; 5.6) 1.2 (-1.3; 3.7) 0.83
Heart rate (beats/
min)
3.6 (0.9; 6.3) 2.2 (-0.6; 4.9) -0.2 (-2.8; 2.4) 1.7 (-1.0; 4.4) 0.09
eGFR (mL/min/
1.73m2)
-2.2 (-4.2; -0.2) -1.3 (-4.5; 1.9) -2.6 (-4.6; -0.7) -3.6 (-6.7; -0.4) 0.60
p-value obtained by baseline adjusted repeated measure analysis (mixed model)—between group change.
2. Visit at 2–3 weeks after baseline visit. eGFR: estimated glomerular filtration rate.
BP: blood pressure
https://doi.org/10.1371/journal.pone.0196962.t002
Table 3. Effect of intervention.
Placebo (n = 31) Ramipril (n = 32)
Estimated Change (95% CI) p  Estimated Change (95% CI) p  p 
Echocardiographic parameters
CFVR 0.26 (0.03; 0.48) 0.026 0.34 (0.11; 0.56) 0.004 0.63
GLS at rest (%) † -0.03 (-0.85; 0. 79) 0.94 -0.24 (-1.07; 0.59) 0.56 0.71
GLS at hyperaemia (%) † -0.03 (-0.91; 0.86) 0.95 -0.17 (-1.06; 0.72) 0.70 0.80
ΔGLS (%) † -0.07 (-1.07; 0.93) 0.89 -0.03 (-1.04; 0.99) 0.96 0.94
LVEF (%) 0.93 (-1.14; 3.00) 0.37 0.56 (-1.47; 2.59) 0.59 0.79
LVMI (g/m2) 0.76 (-5.11; 6.64) 0.80 0.76 (-5.01; 6.53) 0.79 1.00
LAI (mL/m2) 1.44 (-0.89; 3.78) 0.22 1.49 (-0.80; 3.79) 0.20 0.97
Deceleration time (ms) † -9.53 (-22.97; 3.90) 0.16 -18.19 (-31.83; -4.55) 0.01 0.31
E/A ratio † -0.01 (-0.07; 0.05) 0.72 -0.04 (-0.10; 0.02) 0.10 0.47
e’ (cm/s) † 0.14 (-0.41; 0.70) 0.61 -0.09 (-0.63; 0.46) 0.75 0.56
E/e’ ratio † -0.15 (-0.68; 0.38) 0.57 -0.22 (-0.75; 0.32) 0.42 0.86
Burden of symptoms: score by Seattle Angina Questionnaire ‡§
Physical limitation 3.74 (-1.85; 9.33) 0.18 -0.36 (-5.99; 5.28) 0.90 0.31
Angina stability 15.39 (5.20; 25.58) 0.004 27.33 (17.37; 37.29) <0.001 0.07
Angina frequency 5.59 (-2.67; 13.85) 0.18 11.95 (3.91; 19.99) 0.004 0.23
Treatment satisfaction 2.89 (-5.13; 10.91) 0.47 8.24 (0.79; 15.68) 0.03 0.27
Perception/quality of life 2.64 (-4.31; 9.58) 0.45 4.39 (-2.27; 11.06) 0.19 0.71
p-value obtained by baseline adjusted repeated measure analysis (mixed model).
p within group change.
p between group change.
CFVR: Coronary flow velocity reserve, GLS: Global longitudinal strain, LVEF: Left ventricular ejection fraction, LVMI: Left ventricular mass index, LAI: Left atrium
volume (method of discs) index,
†A maximum of 9 observations missing (balanced).
‡ A maximum of 19 pre-and post treatment responses missing (balanced).
§A high score equals a higher functional status.
https://doi.org/10.1371/journal.pone.0196962.t003
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Angina stability improved significantly in both the ramipril (p<0.001) and the placebo
group (p = 0.004). There was an insignificant trend for a larger improvement of angina stabil-
ity in participants treated with ramipril compared with placebo (p = 0.07). Angina frequency
and treatment satisfaction was significantly higher after treatment with ramipril (p = 0.004
and p = 0.03, respectively), but not when compared with placebo (p = 0.23 and p = 0.27,
respectively).
Results obtained by per protocol analyses were similar to the intention to treat analyses.
Adverse reactions
The proportion of participants experiencing an event categorized as either an adverse event,
adverse reaction (common side effects) or serious adverse event was not significantly different
between treatment groups: 20% vs. 18% (p = 0.74), 22% vs. 28% (p = 0.33) and 5% vs. 5%
(p = 0.80), respectively. None of the participants experienced a serious adverse reaction.
Discussion
In this randomized double-blinded placebo-controlled trial of normotensive women with
angina and CMD, we found no significant improvement of coronary microvascular function
assessed by CFVR in participants treated with the ACE inhibitor, ramipril, compared with pla-
cebo. Further, no effect of treatment with ramipril on burden of symptoms or parameters of
left ventricular diastolic and systolic function compared with placebo was detected.
CFVR increased in both groups. This could be a placebo effect and is also likely to be caused
by regression towards the mean because participants were selected into the study based on a
low CFVR at study entry. As expected, systolic and diastolic blood pressure did not change sig-
nificantly for patients treated with ramipril. Based on previous studies in normotensive indi-
viduals with diabetes and microalbuminuria or nephropathies, we assumed no or only modest
blood pressure reduction. In the Heart Outcomes Prevention Evaluation (HOPE) study, rami-
pril (10 mg per day) lowered blood pressure only modestly (by 33/14 mm Hg) in high-risk,
mostly normotensive patients. However, most studies have found no change in blood pressure
[31–38].
A few previous studies have addressed the effect of ACE inhibitor treatment on non-endo-
thelium dependent CMD. In patients with angina and no obstructive CAD, two randomized
placebo-controlled studies of ACE inhibition on coronary microvascular function using intra-
coronary Doppler flow measurements have been conducted. One study (n = 20) showed a sig-
nificant effect of 10 mg enalapril during 2 months of treatment. Mean systolic blood pressure
(SD) was 136 (±20). Drop out was 18% [13]. The other study (n = 61) did not show an effect of
80 mg quinapril over 4 months, but the trial reported an effect in a subanalysis, which was not
pre-specified in the trial protocol, of patients with a baseline CFVR<2.5 (n = 32). Approxi-
mately 40% had hypertension and mean systolic blood pressure was 126 (±19). Drop out was
21% [14]. In a randomized study including patients with CAD (n = 29), no effect of 6 months
of treatment with 40 mg quinapril was found on CFVR assessed by intracoronary Doppler in a
non-stenotic target coronary artery compared with placebo. However, only 13 out of 29 ran-
domized patients completed the study [21]. In a randomized comparator study including
patients with diabetes (n = 24) CFVR assessed by TTDE improved in the group treated with
ACE inhibitor, but the effect was not compared with placebo [17]. Other randomized studies
with a comparator have investigated the effect of treatment with ACE inhibitor on coronary
microvascular function using positron emission tomography (PET) in patients with hyperten-
sion. None of the studies were placebo-controlled and results were inconsistent: One study
observed an improvement in coronary microvascular function in the group treated with ACE
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inhibitor (n = 9) [15], whereas no effect (n = 10, 15) was detected in two of the studies [16,18].
Many small non-randomized studies (n<24) have been conducted using different methods
for assessment of coronary microvascular function. In 2 out of 4 small studies including
hypertensive patients, ACE inhibitor treatment improved coronary microvascular function
[19,20,22,23]. Further, ACE inhibitors in combination with either a calcium antagonist or
indapamide have been shown to be beneficial [24,25]. A small study including patients with
diabetes also showed an effect [26].
Whether the effect of ACE-inhibition on coronary microvascular function in some studies
is indirectly mediated via treatment of hypertension with no direct effect on the microvascula-
ture is uncertain. In support of this, a study found that blood pressure at follow-up after ACE
inhibitor treatment could predict change in CFVR [14]. To our knowledge, no previous studies
investigating coronary microvascular function have focused exclusively on normotensive
patients and contrary to other studies we did not detect an effect compared with placebo.
Therefore, this trial suggests that the effect of ACE inhibition on coronary microvascular func-
tion previously reported could be mediated by blood pressure reduction and that treatment
with ACE inhibition per se does not improve microvascular function.
Studies in patients with angina and no CAD, but a positive stress test or microvascular
angina (CFVR<3) have shown that patients treated with a combination of atorvastatin and
ramipril or quinapril alone, respectively, significantly reduced burden of symptoms compared
with placebo [13,14,51]. In another study of patients with angina, a positive stress test and no
obstructive CAD, burden of symptoms were reduced after treatment with enalapril, but it is
not mentioned whether this reduction is significant when comparing with the placebo group
[13]. In this present study we detected an improvement in the burden of symptoms with ACE
inhibitor treatment, which was not significant when comparing with placebo treatment.
A meta-analysis (39 arms, 1068 patients) has shown that ACE inhibitor treatment reduced
estimated left ventricular mass by a mean of 10% (95% CI 8%; 12%) [52]. However, the studies
included were on patients with hypertension and a more abnormal baseline echocardiography.
Similar to our trial, a study of normotensive patients (n = 46) found no change in LVMI
assessed by TTDE [53]. Furthermore, most participants in this present trial had echocardio-
graphic parameters of left ventricular diastolic function and LVMI within reference range.
Strengths and limitations
The study is a randomized placebo-controlled trial. The participants were included systemati-
cally, and the study is therefore generalizable for normotensive women with CMD and angina
and no obstructive CAD. The primary outcome measure, TTDE CFVR, showed good repro-
ducibility in both healthy individuals and women with angina an no obstructive CAD in our
clinic, and the method for CFVR measurements is accessible and highly feasible [39,40,48].
Differences in resting baseline flow will be reflected in CFVR, i.e. an impaired CFVR may be
due to a high baseline flow. Therefore, part of the variability in the outcome measure can be
due to changes in baseline flow during the trial. However, none of the participants developed
disease states known to influence resting blood flow during the trial such as diabetes or hyper-
tension and furthermore we found no significant difference between changes in hemodynamic
variables, which are also known to influence resting blood flow, in the group randomized to
ACE inhibitors compared with the placebo group.
We intended to include 72 patients to obtain 60 patients completing the study based on a
sample size calculation with 90% power. However, only 63 patients could be included from the
cohort due to a lower inclusion rate than expected, but 55 patients completed the study with
both baseline and follow up measurements (lacking only 5 patients from the original power
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calculation). The SDs on mean CFVR change obtained in this study were larger than hypothe-
sized probably due to a long treatment interval and a divergent treatment response in the rami-
pril group (SD 0.4 and 0.7 in the placebo- and ramipril group, respectively). This implies that
the change in CFVR needs to be more than 0.4 greater in the ramipril group than the placebo
group to detect a significant treatment effect (power set at 80%). Thus, we cannot exclude that
we have overlooked a small but clinically relevant effect of the intervention. The two previous
studies of ACE-inhibition in patients with no obstructive CAD detected an improvement in
CFVR of 0.19 and 1.02 in the intervention group compared with the placebo group, respec-
tively [13,14]. A 13% drop out in this study meets the less than 20% drop out trial quality
criteria.
It could be speculated that a higher dosage might have been more effective in yielding per-
sistent coronary microvascular changes. In this present trial the dose of ramipril ranged from
2.5 to 10.0 mg. Due to lower blood pressure at baseline (<115 mmHg) approximately 40% of
patients ended up on low dose ramipril, whereas 20% were on medium dose ramipril and 40%
on high dose. This was according to the algorithm depicted in Fig 1. However, the maximum
dose in the studies investigating the effect of ACE-inhibitor on CMD varies and there seems to
be no trend of greater effect on coronary microvascular function with higher dosage. In addi-
tion, in the present study no effect of ramipril was detected in subgroups when stratifying by
achieved dosage. However, this study was not powered sufficiently to detect effect in sub-
groups nor was this analysis pre-specified.
Treatment interval was set to 24±6 weeks. Some previous studies looking at coronary
microvascular function as a main endpoint found an effect of treatment with ACE-inhibitors
between 2–4 months [13,14]. However, the effect seen in these studies may be due to the blood
pressure lowering effect of ACE inhibitors. It is possible that a longer treatment period is nec-
essary to result in structural remodelling leading to changes in microvascular function beyond
the blood pressure effect.
Conclusion
Treatment with ACE inhibitor had no significant effect on coronary microvascular function,
echocardiographic parameters of systolic and diastolic function or burden of symptoms com-
pared with placebo in normotensive women with angina and CMD. Thus, current guideline
recommendations of ACE inhibition in treatment of patients with microvascular angina do
not extend to normotensive patients.
Perspectives
Evidence-based treatment options for patients with angina pectoris are lacking. We investi-
gated the efficacy of treatment with the ACE inhibitor ramipril on coronary microvascular
function in normotensive patients with CMD and found no effect compared with placebo,
suggesting that the effect previously detected with ACE-inhibition could be mediated through
blood pressure reduction. This signifies that treatment with ACE inhibitor might only be indi-
cated for the part of angina patients with hypertension. This could be a step towards a more
individualized approach in treating CMD.
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